Screener
D&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Pacira BioSciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.
The source filing: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:07 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-028871
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Cost of goods sold (exclusive of amortization of acquired intangible assets) | 36,413 | 34,306 |
| Research and development | 28,072 | 25,342 |
| Selling, general and administrative | 93,944 | 86,776 |
| Amortization of acquired intangible assets | 14,322 | 14,322 |
| Other operating (gains) expenses, net | (2,277) | 6,187 |
| Total operating expenses | 170,474 | 166,933 |
| Income from operations | 6,902 | 1,990 |
| Other income (expense): |
Item 1. FINANCIAL STATEMENTS (Unaudited)
FAQ
- What is Pacira BioSciences, Inc.'s D&A?
- Pacira BioSciences, Inc. (PCRX) reported D&A of $14.32M in Q1 2026.
- How has Pacira BioSciences, Inc.'s D&A changed year-over-year?
- Pacira BioSciences, Inc.'s D&A decreased by 0.0% year-over-year, from $14.32M to $14.32M.
- What is the long-term trend for Pacira BioSciences, Inc.'s D&A?
- Over 4 years (2021 to 2025), Pacira BioSciences, Inc.'s D&A has grown at a 43.4% compound annual growth rate (CAGR), from $13.55M to $57.29M.
- What does D&A mean?
- Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.
Ask your AI about Pacira BioSciences, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude